- Report
- October 2025
- 196 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- December 2025
- 376 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- March 2025
- 145 Pages
Global
From €2249EUR$2,549USD£1,975GBP
€2645EUR$2,999USD£2,324GBP
- Report
- December 2024
- 144 Pages
Global
From €3484EUR$3,950USD£3,061GBP
- Report
- April 2025
- 100 Pages
Global
From €5248EUR$5,950USD£4,611GBP
- Report
- November 2025
- 191 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- October 2025
- 197 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 186 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 182 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- May 2025
- 200 Pages
Global
From €2196EUR$2,490USD£1,930GBP
- Report
- May 2025
- 106 Pages
Global
From €4190EUR$4,750USD£3,681GBP
- Report
- September 2025
- 250 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- July 2025
- 175 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- April 2025
- 175 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- April 2025
- 175 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- April 2025
- 175 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- April 2025
- 175 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- April 2025
- 175 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- March 2025
- 175 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- December 2025
- 189 Pages
Global
From €5160EUR$5,850USD£4,533GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more